Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
Radiation therapy has never been short on innovation. Scanners capture tumors in remarkable detail, contouring software outlines them with precision, planning tools adapt dosing strategies in real time, and delivery systems deliver radiation with pinpoint accuracy. Each advance has raised the standard of care. But because these tools are often built in silos by different vendors, they rarely speak the same language. Data sits in separate systems, records are transferred manually and the very breakthroughs designed to speed care can create friction where time matters most. Oncosoft, a vendor-neutral platform, resolves this disconnect with an ecosystem designed to unify the entire radiation therapy workflow, from diagnosis through follow-up. In addition to the core modules OncoStudio and OncoFlow, Oncosoft is expanding its treatment stages through the in-development OncoRPT and OncoPlan modules. Slated to be coordinated through Oncosoft’s central AI engine, OncoAgent, this system will automate the complex, repetitive tasks that once consumed hours of clinical effort and ensure information flows securely and continuously across departments. More than 100 hospitals worldwide have already adopted Oncosoft. For them, the value is clear. Oncosoft doesn’t demand a costly rip-and-replace of existing infrastructure. Instead, the vendor-neutral platform is designed for flexible integration with existing Picture Archiving and Communication Systems (PACS), Treatment Planning Systems (TPS), Electronic Medical Records (EMR) and therapy machines by adhering to international standards such as DICOM and HL7. Avoiding vendor lock-in protects past investments, lowers adoption barriers and gives healthcare institutions the freedom to scale on their own terms. “We’re building a solution that benefits the entire healthcare ecosystem,” says Jin Sung Kim, CEO. “Clinicians can focus on what matters most—patient care—instead of inefficient, time-consuming tasks. Hospitals achieve better resource utilization and workflow integration. Most importantly, patients receive faster, more personalized treatment with reduced side effects. It’s about creating better outcomes for everyone.”
Since its establishment in 2010, Remebot has emerged as one of the most influential players in the field of neurosurgical robotics. Headquartered in Beijing, with R&D roots tracing back to 1997, the company has consistently adhered to a philosophy of deeply integrating technological innovation with clinical needs. To date, Remebot has completed over 50,000 clinical procedures and is deployed in more than 550 hospitals worldwide, making it not only a benchmark for "Intelligent Manufacturing in China" but also a significant force shaping the future of global neurosurgery. Remebot’s core competitiveness stems from two pillars: close clinical collaboration and independent mastery of core technologies. The company insists on co-developing solutions with neurosurgeons, ensuring its products address real surgical challenges rather than theoretical possibilities. At the same time, by building its own technological system, Remebot has successfully eliminated dependence on imported components, enabling rapid and precise innovation. The result of this strategy is the company’s pioneering "Brain-Eye-Hand" system architecture, a first-of-its-kind in the industry. Offering a Full Matrix of Systems The Reme-Studio® AI Surgical Planning System serves as the "Brain," enabling oneclick registration, fusion segmentation, and surgical planning. It intelligently segments personalized whole-brain maps covering 95 fine-grained brain subregions, as well as intracranial hematomas, tumors, edema, and functional nuclei, while automatically planning safe surgical paths. The RemeVision® Multispectral Tracking Platform acts as the "Eye," achieving sub-millimeter accuracy (<0.1mm). It supports both optical and infrared markers and features surgical scene reconstruction. The Reme-Explorer Large-Reach Robotic Arm functions as the "Hand," offering six degrees of freedom for fully automated operation and sensitive force feedback. Together, these elements provide surgeons with precision, speed, and confidence in procedures where the margin for error is nearly zero. Remebot’s product family—ranging from theRM-100 and RM-200 to the RM-50, RM-260, RM-150, and RM-50T/B—caters to hospitals across the spectrum, from top-tier medical centers to smaller county-level facilities. This breadth of coverage is one of the company's key strengths in the Asian market, where affordability and adaptability are just as crucial as sophistication. By offering a comprehensive range of systems, Remebot strikes a balance between performance and cost-effectiveness, ensuring that advanced neurosurgical care is accessible to institutions of all levels..
The orthopedic and rehabilitative orthosis industry has long operated within limited boundaries, inadvertently narrowing the spectrum of patient care. With traditional manufacturers’ focus largely on the adult demographic, the specialized needs of pediatric and bariatric populations get sidelined. Enter Restorative Care of America, Inc. (RCAI), a global leader in restorative care products. Its quest to address these gaps not only disrupts traditional market norms but equips patients of all ages and sizes with bespoke, high-caliber solutions, signaling a transformative era in orthotic care. Building on this commitment to broaden inclusivity, RCAI’s pediatric line addresses a critical gap in orthotic solutions. Rather than offering scaled-down versions of adult restorative care products, the company provides innovative solutions that cater to the anatomical requirements of younger patients, ensuring optimal fit, comfort, and functionality. Its bariatric solutions, similarly, are another significant stride toward addressing unique patient needs. Its purpose-built design ensures these solutions harmonize with the specific needs of bariatric patients, reinforcing both comfort and effectiveness. “Our state-of-the-art facility is a testament to our focus on quality. We exercise an unparalleled degree of control over every step of production, which translates to products that meet the highest standards of precision and performance,” says Augustus Turnbull, principal, RCAI. The RCAI Multi Podus Orthosis (MPO) represents one such groundbreaking leap. Its adjustable design allows for customization and adaptability to various foot sizes, democratizing access to orthotic care across diverse patient groups. This innovation simplifies the customization process and streamlines manufacturing, reducing overall production costs.
Medical Imaging Systems
Dr. Jason Chan, Senior Consultant Medical Oncologist, National Cancer Centre Singapore
Medical Imaging Systems
Sayeed Zia, Director, Finance and Corporate Services, Sydney Children's Hospitals
Medical Imaging Systems
Colin Baker, Director Medical Imaging and Pathology Contract, Western Health
Medical Imaging Systems
Janene Lawrence, Clinical Nurse Manager (Medical), Hutt Valley DHB
Medical Imaging Systems
David D. Tran, Chief of Neuro-Oncology and Co-Director of the USC Brain Tumor Center, Keck Medicine of USC
Medical Imaging Systems
Paul Chomiak, MD, Director, Thoracic surgical oncology, Sarasota Memorial Health Care System
Medical Imaging Systems
Armine Smith, Director of Urologic Oncology, Sibley Memorial Hospital
AI-driven radiation therapy solutions in MedTech enhance precision, reduce treatment times, personalize care, and improve clinical outcomes, marking a pivotal shift in modern oncology.
Neurosurgical robotics is revolutionizing surgery with enhanced precision, overcoming challenges, and creating opportunities for growth, innovation, and better patient outcomes.
The New Frontier of Robotic and AI-Driven Medicine
In neurosurgery, precision defines success. Robotic systems now serve as trusted extensions of the surgeon’s skill, translating intent into movements of remarkable accuracy. These systems integrate 3D imaging, motion sensors, and haptic feedback to enhance control and visibility during delicate procedures. Every motion is calculated and deliberate, reducing surgical fatigue and improving outcomes. Through robotics, surgery becomes an experience of amplified precision and human insight working in harmony.
AI-driven radiation therapy is transforming how cancer is treated. Artificial intelligence studies scans, predicts tissue response, and adjusts dosage in real time. This dynamic adaptation ensures tumors receive focused treatment while minimizing damage to surrounding tissue. For patients, it creates a safer and more individualized experience that balances effectiveness with comfort.
Orthopedic care is evolving through smart braces designed to learn from movement and healing patterns. Embedded sensors track alignment, posture, and muscle activity, providing clinicians with live data to personalize rehabilitation. These intelligent supports encourage mobility, enhance comfort, and promote faster recovery.
Each of these advancements reflects a unified goal: to bring precision, adaptability, and empathy to modern medicine. Robotics, AI, and smart materials are enhancing the clinician’s role and elevating the patient experience. The future of care lies in technology that understands the body, supports recovery, and turns treatment into a partnership between science and human resilience.
In this editorial, we are featuring insights from Sayeed Zia, Director of Finance and Corporate Services at Sydney Children’s Hospitals and Janene Lawrence, Clinical Nurse Manager (Medical), at Hutt Valley DHB.
